Connor, Clark & Lunn Investment Management (CC&L)’s Nurix Therapeutics NRIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-62,298
| Closed | -$1.3M | – | 1582 |
|
|
2024
Q2 | $1.3M | Sell |
62,298
-174,806
| -74% | -$3.65M | 0.01% | 783 |
|
|
2024
Q1 | $3.49M | Buy |
237,104
+52,034
| +28% | +$765K | 0.02% | 513 |
|
|
2023
Q4 | $1.91M | Buy |
185,070
+1,147
| +0.6% | +$11.8K | 0.01% | 679 |
|
|
2023
Q3 | $1.45M | Buy |
183,923
+53,429
| +41% | +$420K | 0.01% | 705 |
|
|
2023
Q2 | $1.3M | Buy |
130,494
+117,446
| +900% | +$1.17M | 0.01% | 716 |
|
|
2023
Q1 | $116K | Buy |
+13,048
| New | +$116K | ﹤0.01% | 1140 |
|